[go: up one dir, main page]

MX2017002239A - Composicion que contiene cineol para la administracion nasal. - Google Patents

Composicion que contiene cineol para la administracion nasal.

Info

Publication number
MX2017002239A
MX2017002239A MX2017002239A MX2017002239A MX2017002239A MX 2017002239 A MX2017002239 A MX 2017002239A MX 2017002239 A MX2017002239 A MX 2017002239A MX 2017002239 A MX2017002239 A MX 2017002239A MX 2017002239 A MX2017002239 A MX 2017002239A
Authority
MX
Mexico
Prior art keywords
composition containing
containing film
nasal administration
pharmaceutical composition
nasal
Prior art date
Application number
MX2017002239A
Other languages
English (en)
Inventor
Unkauf Markus
Original Assignee
Maria Clementine Martin Klosterfrau Vertriebsges Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria Clementine Martin Klosterfrau Vertriebsges Mbh filed Critical Maria Clementine Martin Klosterfrau Vertriebsges Mbh
Publication of MX2017002239A publication Critical patent/MX2017002239A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una composición farmacéutica que contiene cineol, destinada para la administración tópica, en particular nasal, preferentemente intranasal así como a su uso y a un dispositivo de administración que contiene esta composición farmacéutica.
MX2017002239A 2014-08-18 2015-06-25 Composicion que contiene cineol para la administracion nasal. MX2017002239A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE102014012040 2014-08-18
DE102014012278 2014-08-22
DE102014013145 2014-09-10
DE102014013189 2014-09-11
DE102014116903.4A DE102014116903A1 (de) 2014-08-18 2014-11-19 Cineolhaltige Zusammensetzung für die nasale Applikation
PCT/EP2015/064373 WO2016026600A1 (de) 2014-08-18 2015-06-25 Cineolhaltige zusammensetzung für die nasale applikation

Publications (1)

Publication Number Publication Date
MX2017002239A true MX2017002239A (es) 2017-05-09

Family

ID=54067266

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002239A MX2017002239A (es) 2014-08-18 2015-06-25 Composicion que contiene cineol para la administracion nasal.

Country Status (12)

Country Link
US (1) US20170273935A1 (es)
EP (2) EP3182957B1 (es)
JP (1) JP6469843B2 (es)
KR (1) KR20170036058A (es)
BR (1) BR112017003164A2 (es)
CL (1) CL2017000394A1 (es)
DE (2) DE102014116903A1 (es)
EA (1) EA033510B1 (es)
ES (2) ES2834985T3 (es)
MX (1) MX2017002239A (es)
PL (1) PL3182957T3 (es)
WO (1) WO2016026600A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202015104410U1 (de) * 2015-07-06 2016-07-13 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die Behandlung von Rhinitis
DE202015104761U1 (de) * 2015-09-01 2016-09-02 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Cineolhaltige wässrige Zusammensetzung für die nasale Applikation
DE102015119541A1 (de) * 2015-10-23 2017-04-27 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Monoterpenhaltige Zusammensetzung zur Behandlung von Erkrankungen der Nase
ES2972897T3 (es) * 2017-08-10 2024-06-17 Elixir Ilac Arastirma Ve Gelistirme A S Composiciones descongestionantes nasales que comprenden mentol, dexpantenol e hialuronato de sodio
EP3552601A1 (de) * 2018-04-11 2019-10-16 Karl Bodenschatz Pharmazeutische zusammensetzung enthaltend dexpanthenol und polihexanid
AT16516U1 (de) * 2019-03-18 2019-11-15 Ulrich Sekotill Mba Nasenspray
JP7649496B2 (ja) * 2020-01-08 2025-03-21 株式会社タフリーインターナショナル 冷感剤組成物
JP2021167307A (ja) * 2020-04-10 2021-10-21 株式会社もんじゅ 鼻腔または上咽頭洗浄用のうがい液
WO2022024087A1 (en) * 2020-07-31 2022-02-03 Bausch & Lomb Ireland Limited Make-up remover wipe formulations
US20220080020A1 (en) * 2020-08-22 2022-03-17 Luc Montagnier Compositions and methods for reducing the transmissivity of illnesses using an oral delivery system
CN112220102B (zh) * 2020-09-25 2022-12-09 山东华熙海御生物医药有限公司 一种含透明质酸和依克多因的电子烟液及其制备方法
US20240050512A1 (en) * 2020-11-25 2024-02-15 Phoxbio Limited Reduction of viral infections
CN120131551B (zh) * 2025-04-03 2025-11-21 西安乐口福泰生物医药科技有限公司 一种鼻炎喷剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1811868A (en) * 1928-08-21 1931-06-30 Rheinische Kampfer Fabrik Process for preparing 1,8-cineol
GB1514469A (en) * 1974-08-01 1978-06-14 Beecham Group Ltd Oral hygiene compositions
HU203667B (en) * 1986-12-11 1991-09-30 Roussel Uclaf Process for producing synergetic zootechnical compositions containing three components
US5114979A (en) * 1989-10-18 1992-05-19 Schering Corporation Fruity flavored nasal decongestant composition
US5854269A (en) * 1993-11-19 1998-12-29 Schering-Plough Healthcare Products, Inc. Nasal spray compositions
DE19549421C2 (de) 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
DE19541919C2 (de) 1995-11-10 1997-11-20 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
DE10107659B4 (de) * 2001-02-19 2008-03-13 Lts Lohmann Therapie-Systeme Ag Mucoadhäsive zerfallsfähige Arzneizubereitung zur Wirkstoffverabreichung in der Veterinär- und Humanmedizin
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
DE20318634U1 (de) 2003-11-13 2004-02-26 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden
DE102007040615A1 (de) * 2007-08-27 2009-03-05 Bitop Ag Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen
CN101292976B (zh) * 2008-06-26 2010-07-28 贵州宏宇药业有限公司 一种含有1,8-桉叶素和艾纳香素的药物组合物及其用途
IT1391170B1 (it) * 2008-08-07 2011-11-18 D M G Italia S R L Composizione topica intra-nasale utilizzabile in caso di ostruzione nasale
DE102012005452A1 (de) * 2011-12-30 2013-07-04 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
DE102013001151A1 (de) * 2013-01-24 2014-07-24 Merz Pharma Gmbh & Co. Kgaa Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit

Also Published As

Publication number Publication date
EA033510B1 (ru) 2019-10-31
CL2017000394A1 (es) 2017-11-03
EP3182957A1 (de) 2017-06-28
EP3300722A1 (de) 2018-04-04
EA201790410A1 (ru) 2017-10-31
JP6469843B2 (ja) 2019-02-13
ES2764506T3 (es) 2020-06-03
KR20170036058A (ko) 2017-03-31
ES2834985T3 (es) 2021-06-21
JP2017525701A (ja) 2017-09-07
US20170273935A1 (en) 2017-09-28
DE202014105553U1 (de) 2015-08-20
EP3300722B1 (de) 2020-09-16
EP3182957B1 (de) 2019-10-16
DE102014116903A1 (de) 2016-02-18
WO2016026600A1 (de) 2016-02-25
PL3182957T3 (pl) 2020-05-18
BR112017003164A2 (pt) 2017-11-28

Similar Documents

Publication Publication Date Title
MX2017002239A (es) Composicion que contiene cineol para la administracion nasal.
IL260852B (en) Methods, devices and systems for pulmonary delivery of active agents
EP3629765A4 (en) DOSAGE ADMINISTRATION FILM
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
BR112016030883A2 (pt) Dispositivo de aerossolização, e, métodos para dispensação de um medicamento aerossolizado e para uso de um dispositivo de aerossol.
EP3429580A4 (en) TERPENANGED CANNABINOID COMPOSITION
IL272278A (en) Local disinfection for drug delivery system
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
HUE039359T2 (hu) Glikopirrónium-bromid és formoterol kombináció stabil, túlnyomásos aeroszol oldat készítménye
EP3303498A4 (en) PHOTOHÄRTBARE ADHESIVE COMPOSITION, THEIR PREPARATION AND USE THEREOF
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
PT3820446T (pt) Composições farmacêuticas que compreendem rpl554 em hfa-134a para administração mediante inalação
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
EA201791716A1 (ru) Фармацевтический состав
BR112018002283A2 (pt) Composição para administração tópica a um sujeito, e, formulação tópica
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
EA201691924A1 (ru) Фармацевтические композиции
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
IL269305A (en) Cannabinoid formulations and dosage